Indeed, nuclear estrogen receptor antagonists such as tamoxifen are a breakthrough in the therapy and the prevention of breast cancer; however, long-term treatment was shown to be associated with an increased risk in endometrial cancer which was explained by the tamoxifen-induced activation of a GPCR, named G protein-coupled estrogen receptor (GPER). Here, GPER1 is linked to breast carcinoma.